Camp4 Therapeutics Corp (CAMP) stock
CAMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3057% above fair value
$3.80−0.29 (-7.09%)
Close on Nov 13, 2026Market cap $238.46MP/E –Yield 0.00%
Camp4 Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Camp4 Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $40.27M, down 0.2% year over year. For fiscal 2025 it was $38.20M, down 1.6% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.20M | -1.6% |
| FY2024 | Dec 31, 2024 | $38.82M | -4.4% |
| FY2023 | Dec 31, 2023 | $40.62M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $11.43M | +16.1% |
| Q2 FY2026 | Jun 30, 2026 | $10.82M | +4.6% |
| Q1 FY2026 | Mar 31, 2026 | $10.16M | +0.1% |
| Q4 FY2025 | Dec 31, 2025 | $7.86M | -21.3% |
| Q3 FY2025 | Sep 30, 2025 | $9.85M | +1.5% |
| Q2 FY2025 | Jun 30, 2025 | $10.34M | +10.2% |
| Q1 FY2025 | Mar 31, 2025 | $10.15M | +4.2% |
| Q4 FY2024 | Dec 31, 2024 | $10.00M | -6.2% |
| Q3 FY2024 | Sep 30, 2024 | $9.70M | -1.2% |
| Q2 FY2024 | Jun 30, 2024 | $9.39M | – |
| Q1 FY2024 | Mar 31, 2024 | $9.74M | – |
| Q4 FY2023 | Dec 31, 2023 | $10.66M | – |
| Q3 FY2023 | Sep 30, 2023 | $9.82M | – |
See a number that looks wrong?